Variables | Time | Nonrenal, n = 72 | p | Renal, n = 105 | p |
---|---|---|---|---|---|
SLEDAI-2K | Baseline | 5.7 ± 4.4 | 13.8 ± 6.5 | ||
6 mos | 4.1 ± 4.1 | < 0.005 | 9.6 ± 5.8 | < 0.0001 | |
12 mos | 4.5 ± 4.8 | 9.0 ± 6.2 | < 0.0001 | ||
No. patients with a SLEDAI-2K decrease by 4 | Baseline | 0 | 0 | ||
6 mos | 15 (20.8) | < 0.05 | 37 (35.2) | < 0.001 | |
12 mos | 13 (18.1) | < 0.05 | 42 (40) | < 0.001 | |
No. of patients with a SLEDAI-2K increase by 4 | Baseline | 0 | 0 | ||
6 mos | 5 (6.9) | 6 (5.7) | |||
12 mos | 7 (9.7) | 0.32 | 6 (5.7) | 1 | |
Clinical SLEDAI-2K, excluding immunological and hematological abnormalities | Baseline | 4.8 ± 4.1 | 12.5 ± 6.2 | ||
6 mos | 3.4 ± 3.8 | 0.0072 | 8.6 ± 5.5 | < 0.001 | |
12 mos | 3.8 ± 4.7 | 0.1332 | 7.9 ± 5.9 | < 0.001 | |
No. patients who reduced prednisone dose | Baseline | 0 | 0 | ||
6 mos | 33 (45.8) | < 0.001 | 66 (62.9) | < 0.0001 | |
12 mos | 44 (61.1) | < 0.001 | 73 (69.5) | < 0.0001 | |
No. patients who increased prednisone dose | Baseline | 19 (26.4) | 33 (31.4) | ||
6 mos | 16 (22.2) | < 0.001 | 18 (17.1) | < 0.001 | |
12 mos | 11 (15.3) | < 0.001 | 15 (14.3) | < 0.001 | |
Average prednisone dose, mg/day | Baseline | 18.4 ± 12.6 | 29.2 ± 16.6 | ||
6 mos | 15.6 ± 10.5 | < 0.05 | 21.2 ± 12.4 | < 0.005 | |
12 mos | 12.1 ± 9.0 | < 0.05 | 15.3 ± 9.7 | < 0.005 | |
MMF dose, mg/day | Baseline | 1350 ± 712.5 | 1687.5 ± 1000 | ||
6 mos | 1512.5 ± 725 | 1625 ± 950 | |||
12 mos | 1662.5 ± 800 | 1687.5 ± 1000 | |||
Anti-dsDNA, Farr assay, + | Baseline | 34 (47.2) | 72 (69.9) | ||
6 mos | 27 (38) | 61 (58.1) | < 0.05 | ||
12 mos | 26 (36.1) | 59 (57.3) | < 0.05 | ||
Low C3 | Baseline | 25 (34.7) | 64 (60.9) | ||
6 mos | 18 (25.0) | < 0.05 | 44 (41.9) | < 0.05 | |
12 mos | 19 (26.4) | < 0.05 | 44 (42.3) | < 0.05 | |
Low C4 | Baseline | 12 (16.7) | 29 (27.6) | ||
6 mos | 8 (11.1) | < 0.05 | 15 (14.3) | < 0.05 | |
12 mos | 7 (9.7) | < 0.05 | 19 (18.3) | < 0.05 |
SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; MMF: mycophenolate mofetil; C3: complement factor 3; C4: complement factor 4.